Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 77
Filter
1.
Pharmacology ; 107(3-4): 235-240, 2022.
Article in English | MEDLINE | ID: mdl-34929695

ABSTRACT

Soluble guanylate cyclase (sGC) plays an important role in nitric oxide (NO)-mediated regulation of vascular tone; however, NO bioavailability is often reduced in diseased blood vessels. Accumulating evidence suggests that a shift of sGC from the NO-sensitive form to the NO-insensitive form could be an underlying cause contributing to this reduction. Herein, we investigated the impact of renovascular hypertension on NO-sensitive and NO-insensitive sGC-mediated relaxation in rat aortas. Renovascular hypertension was induced by partially clipping the left renal artery (2-kidneys, 1-clip; 2K1C) for 10 weeks. Systolic, diastolic, and mean arterial pressures were significantly increased in the 2K1C group when compared with the sham group. In addition, plasma thiobarbituric acid reactive substances and aortic superoxide generation were significantly enhanced in the 2K1C group when compared with those in the sham group. The vasorelaxant response of isolated aortas to the sGC stimulator BAY 41-2272 (NO-sensitive sGC agonist) was comparable between the sham and 2K1C groups. Likewise, the sGC activator BAY 60-2770 (NO-insensitive sGC agonist)-induced relaxation did not differ between the sham and 2K1C groups. In addition, the cGMP mimetic 8-Br-cGMP (protein kinase G agonist) induced similar relaxation in both groups. Furthermore, there were no differences in BAY 41-2272-stimulated and BAY 60-2770-stimulated cGMP generation between the groups. These findings suggest that the balance between NO-sensitive and NO-insensitive forms of sGC is maintained during renovascular hypertension. Therefore, sGC might not be responsible for the reduced NO bioavailability observed during renovascular hypertension.


Subject(s)
Guanylate Cyclase , Hypertension, Renovascular , Animals , Aorta , Cyclic GMP , Nitric Oxide , Rats , Soluble Guanylyl Cyclase
2.
J Vasc Res ; 56(3): 109-116, 2019.
Article in English | MEDLINE | ID: mdl-31085923

ABSTRACT

BACKGROUND/AIMS: Soluble guanylate cyclase (sGC) exists as reduced, oxidized, and heme-free forms. Currently, it is unclear whether endovascular mechanical stenosis has an impact on vascular tone control by drugs targeting sGC, namely cGMP generators. METHODS: Pharmacological responses to acidified sodium nitrite (reduced sGC stimulant) and BAY 60-2770 (oxidized/heme-free sGC stimulant) were studied in balloon-injured rat carotid arteries at several time points. In addition, sGC expression was detected by immunohistochemistry. RESULTS: At 1 day after injury, acidified sodium nitrite-induced relaxation was attenuated in the injured artery, whereas BAY 60-2770-induced relaxation was augmented. Similar attenuation of response to acidified sodium nitrite was seen at 7 and 14 days after injury. On the other hand, the augmentation of response to BAY 60-2770 disappeared at 7 and 14 days after injury. At 1 day after injury, the immunohistochemical expression pattern of sGC in the smooth muscle layer of the injured artery was not different from that of the uninjured artery. However, in the injured artery, the intensity of sGC staining was weak at 7 and 14 days after injury. CONCLUSION: Balloon injury alters vascular responsiveness to cGMP generators, which seems to be associated with the form and/or expression of sGC.


Subject(s)
Benzoates/pharmacology , Biphenyl Compounds/pharmacology , Carotid Artery Injuries/drug therapy , Cyclic GMP/metabolism , Enzyme Activators/pharmacology , Hydrocarbons, Fluorinated/pharmacology , Muscle, Smooth, Vascular/drug effects , Nitric Oxide Donors/pharmacology , Sodium Nitrite/pharmacology , Soluble Guanylyl Cyclase/metabolism , Vasodilation/drug effects , Angioplasty, Balloon , Animals , Carotid Arteries/drug effects , Carotid Arteries/enzymology , Carotid Arteries/pathology , Carotid Artery Injuries/enzymology , Carotid Artery Injuries/pathology , Disease Models, Animal , Enzyme Activation , Male , Muscle, Smooth, Vascular/enzymology , Muscle, Smooth, Vascular/pathology , Rats, Sprague-Dawley , Second Messenger Systems , Time Factors
3.
Circ J ; 82(3): 914-918, 2018 02 23.
Article in English | MEDLINE | ID: mdl-29238009

ABSTRACT

BACKGROUND: The gastroepiploic artery (GEA) plays an important role in the era of multiple arterial revascularization, but spasm is a major matter of concern. The internal thoracic artery has been shown to have a strong tendency to spasm in its distal bifurcating part, whereas the segmental difference in vasoreactivity of the GEA has never been performed.Methods and Results:The full length of the GEA obtained from 21 patients undergoing a total gastrectomy was divided into 3 sections: proximal (5 cm from the origin), middle, and distal (5 cm from the end). Concentration-response curves for vasoconstrictors (phenylephrine, prostaglandin F2α, and endothelin-1) and vasodilators (carperitide, nitroglycerin, and nifedipine) were then established using organ baths. All the vasoconstrictors and vasodilators produced concentration-dependent responses in each section. As the concentration of the vasoconstrictors increased, segments at the distal section showed a significantly greater contraction than those at the middle and proximal sections regardless of the type of vasoconstrictor. The effective concentration of drugs that caused 50% of the maximal response for endothelin-1 was significantly greater in the distal section than that in the proximal sections. No significant difference was found in vasodilators-induced relaxation. CONCLUSIONS: The contractility increases toward to the end of the GEA. Clinically, the distal portion of the GEA should be trimmed off and not be used as an anastomotic site wherever possible.


Subject(s)
Gastroepiploic Artery/physiology , Vasoconstriction/drug effects , Vasoconstrictor Agents/pharmacology , Dinoprost/pharmacology , Dose-Response Relationship, Drug , Endothelin-1/pharmacology , Humans , Phenylephrine/pharmacology , Vasoconstriction/physiology
4.
Heart Vessels ; 33(6): 682-687, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29230572

ABSTRACT

Nitroglycerin is commonly used as an antispasmodic for treating spasm of coronary artery bypass grafts. This study investigated whether the presence of renal failure affects reactivity to nitroglycerin in internal thoracic arteries obtained from patients undergoing coronary bypass surgery. The patients were divided into three groups according to estimated glomerular filtration rate (eGFR, mL/min/1.73 m2): without renal failure (60 ≤ eGFR, n = 13), with moderate renal failure (30 ≤ eGFR < 60, n = 10), and with severe renal failure (eGFR < 30, n = 10). Organ chamber technique was used to evaluate concentration-related responses of isolated internal thoracic arteries to vasodilators. Nitroglycerin induced a concentration-dependent relaxation, which was significantly augmented in patients with severe but not moderate renal failure than in those without renal failure. In addition, there was a negative correlation between eGFR and the relaxant efficacy of nitroglycerin (P = 0.016). On the other hand, relaxant responses to BAY 60-2770 (which enhances cGMP generation as with nitroglycerin) were similar among three grades of renal function. An inverse relationship of eGFR to the relaxant efficacy of BAY 60-2770 was not observed, either (P = 0.314). These findings suggest that severe renal failure specifically potentiates nitroglycerin-induced relaxation in internal thoracic artery grafts.


Subject(s)
Coronary Artery Bypass , Coronary Artery Disease/surgery , Mammary Arteries/physiopathology , Nitroglycerin/pharmacology , Renal Insufficiency/complications , Vasodilation/drug effects , Aged , Coronary Artery Disease/complications , Coronary Artery Disease/physiopathology , Female , Glomerular Filtration Rate , Humans , Intraoperative Period , Male , Mammary Arteries/drug effects , Renal Insufficiency/physiopathology , Vasodilator Agents/pharmacology
5.
Pharmacology ; 99(5-6): 275-280, 2017.
Article in English | MEDLINE | ID: mdl-28249288

ABSTRACT

BACKGROUND/AIMS: Nitroglycerin is widely used as a coronary vasodilator in the treatment of ischemic heart diseases. This study investigated the influence of hypoxia on nitroglycerin-induced relaxation in endothelium-intact and -denuded rabbit, monkey, and porcine coronary arteries. METHODS: Helically cut strips of coronary arteries were suspended in organ chambers, and isometric tension was recorded. RESULTS: Nitroglycerin concentration dependently relaxed endothelium-intact rabbit coronary arteries, which were not different under normoxic and hypoxic conditions. On the other hand, nitroglycerin-induced relaxation of endothelium-denuded arteries was significantly attenuated by hypoxia. Similarly, the relaxant response of endothelium-intact monkey coronary arteries to nitroglycerin was not affected by hypoxia, whereas that of endothelium-denuded arteries was impaired. As is the case with rabbit and monkey coronary arteries, exposure to hypoxia resulted in impaired relaxation by nitroglycerin in endothelium-denuded but not endothelium-intact porcine coronary arteries. CONCLUSION: These findings suggest that coronary endothelium plays a pivotal role in preventing the hypoxia-induced impairment of nitroglycerin responsiveness, regardless of the animal species.


Subject(s)
Coronary Vessels/drug effects , Endothelium, Vascular/drug effects , Endothelium, Vascular/physiology , Hypoxia/physiopathology , Nitroglycerin/pharmacology , Vasodilation/drug effects , Vasodilation/physiology , Animals , Dose-Response Relationship, Drug , Female , In Vitro Techniques , Macaca , Male , Rabbits , Swine
6.
Pflugers Arch ; 468(9): 1517-25, 2016 09.
Article in English | MEDLINE | ID: mdl-27417104

ABSTRACT

Increasing evidence support the idea that hyperhomocysteinemia (HHcy) is responsible for pathogenesis underlying cerebral, coronary, renal, and other vascular circulatory disorders and for hypertension. Impaired synthesis of nitric oxide (NO) in the endothelium or increased production of asymmetric dimethylarginine and activated oxygen species are involved in the impairment of vasodilator effects of NO. Impaired circulation in the brain derived from reduced synthesis and actions of NO would be an important triggering factor to dementia and Alzheimer's disease. Reduced actions of NO and brain hypoperfusion trigger increased production of amyloid-ß that inhibits endothelial function, thus establishing a vicious cycle for impairing brain circulation. HHcy is involved in the genesis of anginal attack and coronary myocardial infarction. HHcy is also involved in renal circulatory diseases. The homocysteine (Hcy)-induced circulatory failure is promoted by methionine and is prevented by increased folic acid and vitamin B6/B12. Eliminating poor life styles, such as smoking and being sedentary; keeping favorable dietary habits; and early treatment maintaining constitutive NOS functions healthy, reducing oxidative stresses would be beneficial in protecting HHcy-induced circulatory failures.


Subject(s)
Cerebrovascular Circulation , Coronary Circulation , Hyperhomocysteinemia/metabolism , Nitric Oxide Synthase Type III/metabolism , Nitric Oxide Synthase Type I/metabolism , Animals , Humans , Hyperhomocysteinemia/enzymology , Hyperhomocysteinemia/physiopathology
7.
J Pharmacol Sci ; 131(4): 223-32, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27530818

ABSTRACT

Cerebral blood flow is mainly regulated by nitrergic (parasympathetic, postganglionic) nerves and nitric oxide (NO) liberated from endothelial cells in response to shear stress and stretch of vasculature, whereas sympathetic vasoconstrictor control is quite weak. On the other hand, peripheral vascular resistance and blood flow are mainly controlled by adrenergic vasoconstrictor nerves; endothelium-derived NO and nitrergic nerves play some roles as vasodilator factors. Cigarette smoking impairs NO synthesis in cerebral vascular endothelial cells and nitrergic nerves leading to interference with cerebral blood flow and glucose metabolism in the brain. Smoking-induced cerebral hypoperfusion is induced by impairment of synthesis and actions of NO via endothelial nitric oxide synthase (eNOS)/neuronal NOS (nNOS) inhibition and by increased production of oxygen radicals, resulting in decreased actions of NO on vascular smooth muscle. Nicotine acutely and chronically impairs the action of endothelial NO and also inhibits nitrergic nerve function in chronic use. Impaired cerebral blood supply promotes the synthesis of amyloid ß that accelerates blood flow decrease. This vicious cycle is thought to be one of the important factors involving in Alzheimer's disease (AD). Quitting smoking is undoubtedly one of the important ways to prevent and delay the genesis or slow the progress of impaired cognitive function and AD.


Subject(s)
Alzheimer Disease/physiopathology , Cerebrovascular Circulation/physiology , Muscle, Smooth, Vascular/physiology , Nitric Oxide/physiology , Smoking/physiopathology , Alzheimer Disease/metabolism , Endothelium, Vascular/metabolism , Humans , Models, Biological , Nitric Oxide/metabolism , Nitric Oxide Synthase Type I/metabolism , Nitric Oxide Synthase Type III/metabolism , Smoking/metabolism
8.
Pflugers Arch ; 467(6): 1165-78, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25339222

ABSTRACT

Cerebral vascular resistance and blood flow were widely considered to be regulated solely by tonic innervation of vasoconstrictor adrenergic nerves. However, pieces of evidence suggesting that parasympathetic nitrergic nerve activation elicits vasodilatation in dog and monkey cerebral arteries were found in 1990. Nitric oxide (NO) as a neurotransmitter liberated from parasympathetic postganglionic neurons decreases cerebral vascular tone and resistance and increases cerebral blood flow, which overcome vasoconstrictor responses to norepinephrine liberated from adrenergic nerves. Functional roles of nitrergic vasodilator nerves are found also in peripheral vasculature, including pulmonary, renal, mesenteric, hepatic, ocular, uterine, nasal, skeletal muscle, and cutaneous arteries and veins; however, adrenergic nerve-induced vasoconstriction is evidently greater than nitrergic vasodilatation in these vasculatures. In coronary arteries, neurogenic NO-mediated vasodilatation is not clearly noted; however, vasodilatation is induced by norepinephrine released from adrenergic nerves that activates ß1-adrenoceptors. Impaired actions of NO liberated from the endothelium and nitrergic neurons are suggested to participate in cerebral hypoperfusion, leading to brain dysfunction, like that in Alzheimer's disease. Nitrergic neural dysfunction participates in impaired circulation in peripheral organs and tissues and also in systemic blood pressure increase. NO and vasodilator peptides, as sensory neuromediators, are involved in neurogenic vasodilatation in the skin. Functioning of nitrergic vasodilator nerves is evidenced not only in a variety of mammals, including humans and monkeys, but also in non-mammals. The present review article includes recent advances in research on the functional importance of nitrergic nerves concerning the control of cerebral blood flow, as well as other regions, and vascular resistance. Although information is still insufficient, the nitrergic nerve histology and function in vasculatures of non-mammals are also summarized.


Subject(s)
Muscle, Smooth, Vascular/physiology , Nitrergic Neurons/metabolism , Nitric Oxide/metabolism , Vasodilation , Animals , Humans , Muscle, Smooth, Vascular/innervation , Muscle, Smooth, Vascular/metabolism , Nitrergic Neurons/physiology
9.
Biochem Biophys Res Commun ; 468(1-2): 208-13, 2015.
Article in English | MEDLINE | ID: mdl-26519878

ABSTRACT

Mitochondrial oxidative capacity in skeletal muscle is known to decrease in diabetic patients, and sarcopenia is a risk factor for diabetes, particularly in elderly people. We previously revealed that microRNA (miR)-494 inhibits mitochondrial biogenesis during myogenic differentiation in murine C2C12 cells and others reported that exercise regulates miR-494 levels in obese sedentary individuals with increased risk of type 2 diabetes. In this study, to investigate the therapeutic potential of miR-494, we first investigated the role of miR-494 during human skeletal myogenesis. Using human induced pluripotent stem (hiPS) cells stably transfected with the Tet/ON-myogenic differentiation 1(MYOD1) gene (MyoD-hiPS cells), we found that miR-494 expression transiently increased and was downregulated after myogenic induction. In miR-494 transfected MyoD-hiPS cells, the level of high oxidative fiber (type IIa) marker proteins specifically decreased, while no change in the total number of cells was observed. In contrast, the expression of both type I and type IIx markers was unaffected by miR-494 overexpression. Furthermore, miR-494 overexpression suppressed basal oxygen consumption rate concomitant with the inhibition of myotube formation and without significant effects on the mitochondrial content. These results suggest that miR-494 plays a novel role in the fiber type-specific skeletal myogenesis in MyoD-hiPS cells, distinct from murine C2C12 myogenesis.


Subject(s)
Induced Pluripotent Stem Cells/metabolism , MicroRNAs/genetics , Muscle Development , Muscle Fibers, Skeletal/metabolism , Muscle, Skeletal/growth & development , Cell Line , Down-Regulation , Gene Expression Regulation, Developmental , Humans , Induced Pluripotent Stem Cells/cytology , MicroRNAs/metabolism , Mitochondria, Muscle/metabolism , Muscle Fibers, Skeletal/cytology , Muscle, Skeletal/metabolism , Up-Regulation
10.
J Cardiovasc Pharmacol ; 65(2): 160-7, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25329747

ABSTRACT

Superoxide production is increased in diseased blood vessels, which is considered to lead to impairment of the nitric oxide (NO)/soluble guanylate cyclase (sGC)/cGMP pathway. To investigate the respective influence of extracellular and intracellular superoxide on vascular function through the NO/sGC/cGMP pathway, mechanical responses of rat external iliac arteries without endothelium were studied under exposure to a superoxide-generating agent, pyrogallol, or menadione. Exposure to pyrogallol impaired the relaxation induced by acidified NaNO2 (exogenous NO) but not that by nitroglycerin (organic nitrate), BAY 41-2272 (sGC stimulator), BAY 60-2770 (sGC activator), or 8-Br-cGMP (cGMP analog). Superoxide dismutase (SOD) and tempol restored the impaired relaxation by acidified NaNO2. Superoxide production in the bathing solution, but not in artery segments, was significantly increased by exposure to pyrogallol, which was abolished in the presence of SOD or tempol. However, exposure to menadione impaired the relaxant response to acidified NaNO2, nitroglycerin, or BAY 41-2272, whereas it augmented that to BAY 60-2770. Also, this exposure had no effect on the 8-Br-cGMP-induced vasorelxation. Superoxide production in artery segments was dramatically enhanced by exposure to menadione, whereas that in the bathing solution was not affected. This increase in vascular superoxide production was normalized by tempol but not by SOD. These findings suggest that extracellular superoxide reacts with NO only outside the cell, whereas intracellular superoxide not only scavenges NO inside the cell but also shifts the sGC redox equilibrium.


Subject(s)
Cyclic GMP/metabolism , Guanylate Cyclase/metabolism , Muscle Relaxation , Muscle, Smooth, Vascular , Nitric Oxide/metabolism , Receptors, Cytoplasmic and Nuclear/metabolism , Superoxides/metabolism , Animals , Benzoates/pharmacology , Biphenyl Compounds/pharmacology , Cyclic GMP/analogs & derivatives , Cyclic GMP/pharmacology , Cyclic GMP-Dependent Protein Kinases/antagonists & inhibitors , Hydrocarbons, Fluorinated/pharmacology , Iliac Artery , Male , Muscle Relaxation/drug effects , Muscle Relaxation/physiology , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/physiology , Oxidative Stress/drug effects , Oxidative Stress/physiology , Pyrazoles/pharmacology , Pyridines/pharmacology , Rats , Rats, Sprague-Dawley , Signal Transduction/drug effects , Signal Transduction/physiology , Soluble Guanylyl Cyclase , Vasodilation/drug effects , Vasodilation/physiology
11.
J Vasc Res ; 51(6): 439-46, 2014.
Article in English | MEDLINE | ID: mdl-25634663

ABSTRACT

BACKGROUND/AIMS: The present study investigated the mechanism by which peroxynitrite impairs vascular function through the nitric oxide (NO)/soluble guanylate cyclase (sGC)/cGMP pathway. METHODS: Mechanical responses of rat external iliac arteries without endothelium were studied under exposure to peroxynitrite. cGMP concentrations were determined by enzyme immunoassay. RESULTS: Relaxation induced by BAY 41-2272 (sGC stimulator) was impaired under exposure to peroxynitrite, whereas that by BAY 60-2770 (sGC activator) was enhanced. These responses were correlated with tissue levels of cGMP. Effects of peroxynitrite on the relaxant responses to BAY compounds were also observed in the presence of superoxide dismutase (SOD) or tempol, both of which scavenge a certain kind of reactive molecules other than peroxynitrite. As is the case with the relaxant response to BAY 41-2272, acidified NaNO2- and nitroglycerin-induced relaxations were markedly attenuated by exposing the arteries to peroxynitrite, which was not abolished by preincubation with SOD or tempol. On the other hand, peroxynitrite exposure had no effect on the 8-Br-cGMP-induced vasorelxation. CONCLUSION: These findings suggest that peroxynitrite interferes with the NO/sGC/cGMP pathway by altering the redox state of sGC. It is likely that peroxynitrite can shift the sGC redox equilibrium to the NO-insensitive state in the vasculature.


Subject(s)
Cyclic GMP/metabolism , Guanylate Cyclase/metabolism , Iliac Artery/drug effects , Nitric Oxide/metabolism , Peroxynitrous Acid/pharmacology , Receptors, Cytoplasmic and Nuclear/metabolism , Vasodilation/drug effects , Animals , Antioxidants/pharmacology , Dose-Response Relationship, Drug , Enzyme Activation , Enzyme Activators/pharmacology , Iliac Artery/enzymology , Male , Oxidation-Reduction , Rats, Sprague-Dawley , Second Messenger Systems/drug effects , Soluble Guanylyl Cyclase , Vasodilator Agents/pharmacology
12.
J Pharmacol Sci ; 125(2): 169-75, 2014.
Article in English | MEDLINE | ID: mdl-24859780

ABSTRACT

Hypoxia or hypoxia/reoxygenation impairs nitric oxide (NO)-mediated relaxation through the increase in superoxide generation in monkey coronary arteries. Soluble guanylate cyclase (sGC), the target enzyme of NO, has been shown to change from the NO-sensitive reduced form to the NO-insensitive oxidized/heme-free form under substantial oxidative stress, so the present study investigated whether hypoxia or hypoxia/reoxygenation influences sGC redox equilibrium. In isolated monkey coronary arteries without endothelium, the relaxation caused by the sGC stimulator BAY 41-2272 (Emax: 93.3% ± 2.2%) was somewhat impaired under hypoxia (Emax: 86.3% ± 2.6%) or hypoxia/reoxygenation (Emax: 86.1% ± 3.2%), whereas that by the sGC activator BAY 60-2770 (Emax: 86.0% ± 3.2%) was significantly augmented under hypoxia (Emax: 94.4% ± 1.3%) or hypoxia/reoxygenation (Emax: 95.5% ± 1.1%). In addition, cGMP formation in response to BAY 41-2272 and BAY 60-2770 was inhibited and stimulated, respectively, under hypoxia or hypoxia/reoxygenation. The effects of hypoxia or hypoxia/reoxygenation on BAY 41-2272- and BAY 60-2770-induced vasorelaxation were completely canceled by the treatment with the superoxide dismutase mimetic tempol. These findings suggest that sGC redox equilibrium in the coronary artery is shifted towards the NO-insensitive form under hypoxia or hypoxia/reoxygenation and that superoxide seems to play an important role in this shift.


Subject(s)
Coronary Vessels/enzymology , Coronary Vessels/physiopathology , Guanylate Cyclase/metabolism , Hypoxia/enzymology , Hypoxia/physiopathology , Superoxides/metabolism , Vasodilation , Animals , Benzoates/antagonists & inhibitors , Benzoates/pharmacology , Biphenyl Compounds/antagonists & inhibitors , Biphenyl Compounds/pharmacology , Coronary Vessels/metabolism , Cyclic GMP/metabolism , Female , Hydrocarbons, Fluorinated/antagonists & inhibitors , Hydrocarbons, Fluorinated/pharmacology , Hypoxia/metabolism , In Vitro Techniques , Macaca , Male , Nitric Oxide/metabolism , Nitric Oxide/physiology , Oxidation-Reduction , Oxidative Stress , Pyrazoles/antagonists & inhibitors , Pyrazoles/pharmacology , Pyridines/antagonists & inhibitors , Pyridines/pharmacology , Solubility , Superoxide Dismutase/pharmacology , Vasodilation/drug effects
13.
J Pharmacol Sci ; 124(1): 76-85, 2014.
Article in English | MEDLINE | ID: mdl-24389820

ABSTRACT

Deficiency of tetrahydrobiopterin (BH4) in the vascular tissue contributes to endothelial dysfunction through reduced eNOS activity and increased superoxide anion (O2(-)) generation in the insulin-resistant state. We investigated the effects of atorvastatin, a 3-hydroxyl-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor; amlodipine, a calcium antagonist; and their combination on blood pressure, arterial relaxation and contraction, and vascular oxidative stress in aortas of high fructose-fed rats. Oral administration of atorvastatin for 8 weeks did not significantly lower blood pressure, but normalized angiotensin II-induced vasoconstriction and endothelial function in the fructose-fed rats. Atorvastatin treatment of fructose-fed rats increased vascular BH4 content, which was associated with an increase in endothelial NO synthase activity as well as a reduction in endothelial O2(-) production. On the other hand, administration of amlodipine did not affect the angiotensin II-induced vasoconstriction and endothelial function, but normalized the elevated blood pressure in the fructose-fed rats. The combined treatment did not show synergistic but additive beneficial effects. The present study suggests that combined therapy of HMG-CoA reductase inhibitors and calcium antagonists prevents functional vascular disorders in the insulin-resistant state, possibly resulting in the protection against or delay of development of hypertension, vascular dysfunction in diabetes, and thereafter atherosclerosis.


Subject(s)
Amlodipine/pharmacology , Calcium Channel Blockers/pharmacology , Cardiovascular Diseases/prevention & control , Cardiovascular Diseases/physiopathology , Heptanoic Acids/pharmacology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Insulin Resistance , Pyrroles/pharmacology , Animals , Atorvastatin , Biopterins/analogs & derivatives , Biopterins/metabolism , Biopterins/physiology , Blood Pressure/drug effects , Cardiovascular Diseases/etiology , Disease Models, Animal , Drug Therapy, Combination , Endothelium, Vascular/drug effects , Fructose/administration & dosage , Fructose/adverse effects , Male , Nitric Oxide/metabolism , Nitric Oxide Synthase Type III/metabolism , Rats , Rats, Sprague-Dawley , Superoxides/metabolism , Vasoconstriction/drug effects , Vasodilation/drug effects
14.
J Pharmacol Sci ; 126(2): 168-71, 2014.
Article in English | MEDLINE | ID: mdl-25242170

ABSTRACT

Metabolic syndrome (MetS) induces serious complications; therefore, we developed a noninvasive MetS model using an extremely small minipig, the Microminipig. For 8 weeks, Microminipigs were administrated a high-fat and high-cholesterol diet (HFCD) for atherosclerosis and N(G)-nitro-l-arginine methyl ester (l-NAME) for inhibiting nitric oxide synthase. HFCD significantly increased serum low-density lipoprotein levels, l-NAME increased blood pressure and cardiac hypertrophy, and HFCD-induced aortal arteriosclerosis was accelerated by l-NAME administration. Endothelium-dependent relaxation of the coronary artery was remarkably decreased by l-NAME administration. This model may be useful for elucidating the mechanisms of MetS and developing new therapeutic medicines for its treatment.


Subject(s)
Cholesterol, Dietary/administration & dosage , Diet, High-Fat , Disease Models, Animal , Metabolic Syndrome , Swine, Miniature , Animals , Atherosclerosis/etiology , Blood Pressure/drug effects , Cardiomegaly/chemically induced , Cholesterol, Dietary/adverse effects , Coronary Vessels/drug effects , Diet, High-Fat/adverse effects , Drug Discovery , Endothelium, Vascular/physiology , Lipoproteins, LDL/blood , Male , Metabolic Syndrome/drug therapy , Metabolic Syndrome/etiology , Metabolic Syndrome/physiopathology , Muscle Relaxation/drug effects , Muscle, Smooth, Vascular/drug effects , NG-Nitroarginine Methyl Ester/administration & dosage , NG-Nitroarginine Methyl Ester/adverse effects , Nitric Oxide Synthase/antagonists & inhibitors , Swine
15.
Pharmacology ; 91(5-6): 322-30, 2013.
Article in English | MEDLINE | ID: mdl-23797011

ABSTRACT

Individual vascular beds exhibit differences in vascular reactivity. The present study examined the influence of hypoxia on endothelium-dependent, especially nitric oxide (NO)-mediated, relaxation in the isolated rat common carotid, superior mesenteric and external iliac arteries. Hypoxia for 1 and 3 h had no effects on the relaxations caused by acetylcholine (ACh) and sodium nitroprusside (SNP) in common carotid and external iliac arteries. In addition, NO synthase inhibitor N(G)-nitro-L-arginine (L-NA, 10 µmol/l)-resistant, endothelium-dependent relaxations by ACh were also unaffected by hypoxia in these arteries. On the other hand, ACh-induced relaxation in superior mesenteric arteries was significantly impaired by exposure to hypoxia, while this condition did not affect the relaxation induced by SNP or ACh in the presence of L-NA. This impairment was partially prevented by treatment with tempol (3 mmol/l), a superoxide scavenger. These findings demonstrate a marked heterogeneity in response to hypoxia in rat arteries. Briefly, acute hypoxia induces impairment of endothelium-derived NO-mediated relaxation through the decrease in its bioavailability in the superior mesenteric, but not in common carotid or external iliac, arteries. Furthermore, superoxide seems to be one causal factor responsible for the undesirable effect of hypoxia.


Subject(s)
Carotid Arteries/physiopathology , Hypoxia/physiopathology , Iliac Artery/physiopathology , Mesenteric Arteries/physiopathology , Nitric Oxide/physiology , Animals , In Vitro Techniques , Male , Rats , Rats, Sprague-Dawley , Superoxides/metabolism , Vasodilation/physiology
16.
J Cardiovasc Pharmacol ; 60(1): 100-8, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22407338

ABSTRACT

Blood flow in oral tissues, including the tongue, salivary glands, gingiva, dental pulp, and lip, plays an important role in modulating the complex oral functions involved in food intake. Oral tissue circulation is regulated by nitric oxide (NO) synthesized by neuronal NO synthase mainly present in parasympathetic vasodilator neurons and also by endothelial NO sythase. Electrical stimulation of parasympathetic nerves causes vasodilatation and blood flow increase in the tongue, submandibular gland, and lip in various mammals in vitro and in vivo. Lingual arteries isolated from Japanese monkeys respond to perivascular nerve stimulation by electrical pulses and nicotine with relaxations that are mediated via neurogenic NO. There is evidence supporting the hypothesis that the superior salivatory nucleus delivers central information through the geniculate ganglion and greater petrosal nerve to the pterygopalatine ganglion, which sends off impulses through nitrergic nerves to oral tissues. Endothelial NO also plays an important role in improving oral blood circulation not only in resting conditions but also under conditions activated by chemical and physical stimuli in the tongue, submandibular and parotid glands, dental pulp/gingiva, and cheek pouch. Maintenance of health in oral circulation by minimizing factors responsible for impairment of endothelial and neurogenic NO bioavailability would be important for the prophylaxis of life-style related diseases.


Subject(s)
Mouth/blood supply , Nitric Oxide/metabolism , Tongue/blood supply , Animals , Endothelium/metabolism , Humans , Mouth/physiology , Mouth Diseases/etiology , Mouth Diseases/prevention & control , Nitrergic Neurons/metabolism , Nitric Oxide Synthase Type I/metabolism , Nitric Oxide Synthase Type III/metabolism , Oral Health , Tongue/physiology
17.
J Cardiovasc Pharmacol ; 60(1): 55-60, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22494993

ABSTRACT

Angiotensin type 1 receptor (AT1R) antagonist and endothelin type A receptor (ET(A)R) antagonist were compared as regards their effects on ischemia-induced exocytotic or carrier-mediated norepinephrine (NE) release from cardiac sympathetic nerve endings. According to the Langendorff technique, isolated rat hearts were subjected to 20-minute or 40-minute global ischemia followed by 30-minute reperfusion. Candesartan (selective AT1R antagonist) and ABT-627 (selective ET(A)R antagonist) were perfused, beginning 15 minutes before ischemia. Candesartan (10 and 100 nM) and ABT-627 (3 µM) suppressed excessive NE overflow (exocytotic release) in the coronary effluent from the heart exposed to 20-minute ischemia. In addition, these agents improved postischemic cardiac dysfunction. On the other hand, the beneficial effects of ABT-627 (1 and 3 µM) on NE overflow (carrier-mediated release) and cardiac dysfunction were also observed in 40-minute ischemia, whereas those were not improved by treatment with candesartan (10 and 100 nM and 1 µM). These findings suggest that both AT1R antagonist and ET(A)R antagonist have ability to inhibit the exocytotic NE release, but the carrier-mediated NE release induced by prolonged ischemia cannot be avoided by AT1R antagonist. Thus, ET(A)R antagonist may be more useful than AT1R antagonist in the clinical settings of ischemic heart disease.


Subject(s)
Benzimidazoles/pharmacology , Myocardial Ischemia/drug therapy , Myocardial Reperfusion Injury/drug therapy , Pyrrolidines/pharmacology , Tetrazoles/pharmacology , Angiotensin II Type 1 Receptor Blockers/administration & dosage , Angiotensin II Type 1 Receptor Blockers/pharmacology , Animals , Atrasentan , Benzimidazoles/administration & dosage , Biphenyl Compounds , Disease Models, Animal , Dose-Response Relationship, Drug , Endothelin A Receptor Antagonists , Male , Myocardial Ischemia/physiopathology , Myocardial Reperfusion Injury/physiopathology , Norepinephrine/metabolism , Pyrrolidines/administration & dosage , Rats , Rats, Sprague-Dawley , Tetrazoles/administration & dosage , Time Factors
18.
J Pharmacol Sci ; 118(2): 206-14, 2012.
Article in English | MEDLINE | ID: mdl-22302022

ABSTRACT

Cigarette smoking has been implicated in the initiation and progression of cardiovascular disorders and atherosclerosis. Here, we examined the effects of nicotine-free cigarette smoke extract (CSE) on the regulation of cardiovascular function. Rats were subcutaneously administered PBS or nicotine-free CSE at 0.05 to 1.5 mL/day per rat for 4 weeks. Blood pressure, cardiac function, and vascular responsiveness were measured at 4 weeks after administration. Furthermore, acute effects of nicotine-free CSE were also studied in the aorta isolated from normal rats. Blood pressure and left ventricular systolic pressure (LVSP) were significantly increased in the nicotine-free CSE-administered rats, but heart rate, dP/dt(max), and dP/dt(min) were not affected. Endothelium-dependent relaxation by acetylcholine (ACh) in the nicotine-free CSE-treated rats was significantly attenuated compared to PBS-treated rats, but endothelium-independent relaxation by sodium nitroprusside (SNP) did not differ. Pretreatment with superoxide dismutase restored the attenuated ACh-induced relaxation. Contractions by phenylephrine, angiotensin II, and KCl did not differ between two groups. In vitro acute nicotine-free CSE treatment did not alter the response to ACh or SNP. These results suggest that chronic nicotine-free CSE administration impairs endothelial function by increased production of superoxide derived from the vascular wall components other than smooth muscles and induces slight hypertension accompanied with LVSP elevation.


Subject(s)
Endothelium, Vascular/drug effects , Nicotiana/chemistry , Smoke/adverse effects , Vasodilation/drug effects , Acetylcholine/pharmacology , Animals , Aorta, Thoracic/drug effects , Aorta, Thoracic/metabolism , Blood Pressure/drug effects , Endothelium, Vascular/pathology , Heart Rate/drug effects , Male , Nitroprusside/pharmacology , Oxidative Stress/drug effects , Rats , Rats, Sprague-Dawley , Superoxide Dismutase/pharmacology
19.
Pharmacol Rev ; 61(1): 62-97, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19293146

ABSTRACT

Nitric oxide (NO) is undoubtedly quite an important intercellular messenger in cerebral and peripheral hemodynamics. This molecule, formed by constitutive isomers of NO synthase, endothelial nitric-oxide synthase, and neuronal nitric-oxide synthase, plays pivotal roles in the regulation of cerebral blood flow and cell viability and in the protection of nerve cells or fibers against pathogenic factors associated with cerebral ischemia, trauma, and hemorrhage. Cerebral blood flow is increased and cerebral vascular resistance is decreased by NO derived from endothelial cells, autonomic nitrergic nerves, or brain neurons under resting and stimulated conditions. Somatosensory stimulation also evokes cerebral vasodilatation mediated by neurogenic NO. Oxygen and carbon dioxide alter cerebral blood flow and vascular tone mainly via constitutively formed NO. Endothelial dysfunction impairs cerebral hemodynamics by reducing the bioavailability of NO and increasing the production of reactive oxygen species (ROS). The NO-ROS interaction is an important issue in discussing blood flow and cell viability in the brain. Recent studies on brain circulation provide quite useful information concerning the physiological roles of NO produced by constitutive isoforms of nitric-oxide synthase and how NO may promote cerebral pathogenesis under certain conditions, including cerebral ischemia/stroke, cerebral vasospasm after subarachnoid hemorrhage, and brain injury. This information would contribute to better understanding of cerebral hemodynamic regulation and its dysfunction and to development of novel therapeutic measures to treat diseases of the central nervous system.


Subject(s)
Cerebrovascular Circulation/physiology , Nitric Oxide Synthase/metabolism , Nitric Oxide/physiology , Humans , Neurons/metabolism , Reactive Oxygen Species/metabolism , Vasodilation
20.
Vascul Pharmacol ; 145: 107023, 2022 08.
Article in English | MEDLINE | ID: mdl-35718342

ABSTRACT

Soluble guanylate cyclase (sGC) plays an important role in maintaining vascular homeostasis, as an acceptor for the biological messenger nitric oxide (NO). However, only reduced sGC (with a ferrous heme) can be activated by NO; oxidized (ferric heme) and apo (absent heme) sGC cannot. In addition, the proportions of reduced, oxidized, and apo sGC change under pathological conditions. Although diseased blood vessels often show decreased NO bioavailability in the vascular wall, a shift of sGC heme redox balance in favor of the oxidized/apo forms can also occur. Therefore, sGC is of growing interest as a drug target for various cardiovascular diseases. Notably, the balance between NO-sensitive reduced sGC and NO-insensitive oxidized/apo sGC in the body is regulated in a reversible manner by various biological molecules and proteins. Many studies have attempted to identify endogenous factors and determinants that influence this redox state. For example, various reactive nitrogen and oxygen species are capable of inducing the oxidation of sGC heme. Conversely, a heme reductase and some antioxidants reduce the ferric heme in sGC to the ferrous state. This review summarizes the factors and mechanisms identified by these studies that operate to regulate the sGC heme redox state.


Subject(s)
Heme , Nitric Oxide , Guanylate Cyclase/metabolism , Heme/metabolism , Nitric Oxide/metabolism , Nitrogen , Oxidation-Reduction , Oxidoreductases/metabolism , Oxygen , Soluble Guanylyl Cyclase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL